Details for: CLINIMIX E
Product description
Product name: CLINIMIX E
Company name: BAXTER CORPORATION
DIN: 02498421
Status: Marketed
Status date: 2020-12-01
Active ingredient(s) | Strength |
---|---|
ALANINE | 1656 MG / 100 ML |
CALCIUM CHLORIDE | 33 MG / 100 ML |
DEXTROSE | 14 G / 100 ML |
GLYCINE | 824 MG / 100 ML |
HISTIDINE | 384 MG / 100 ML |
L-ARGININE | 920 MG / 100 ML |
L-ISOLEUCINE | 480 MG / 100 ML |
L-LEUCINE | 584 MG / 100 ML |
L-LYSINE HYDROCHLORIDE | 464 MG / 100 ML |
L-PHENYLALANINE | 448 MG / 100 ML |
L-PROLINE | 544 MG / 100 ML |
L-THREONINE | 336 MG / 100 ML |
L-TYROSINE | 32 MG / 100 ML |
L-VALINE | 464 MG / 100 ML |
MAGNESIUM CHLORIDE | 24 MG / 100 ML |
METHIONINE | 320 MG / 100 ML |
POTASSIUM PHOSPHATE DIBASIC | 261 MG / 100 ML |
SERINE | 400 MG / 100 ML |
SODIUM CHLORIDE | 205 MG / 100 ML |
TRYPTOPHAN | 144 MG / 100 ML |
Resources
Click on a resource to visit a page with more information. You may be taken away from this page to a different Government of Canada website.
For consumers
Resource | Description |
---|---|
Product Monograph |
The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use. The Product Monograph includes three sections:
|
Regulatory Decision Summary for Clinimix / Clinimix E |
The Regulatory Decision Summary explains Health Canada’s decision for the product seeking market authorization. The Regulatory Decision Summary includes the purpose of the submission and the reason for the decision. |
Report a side effect |
Side effects are troublesome symptoms or feelings that you may not expect that show up when you are taking a medicine. All suspected side effects should be reported, especially those that are:
|
For health care professionals
Resource | Description |
---|---|
Product Monograph |
The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use. The Product Monograph includes three sections:
|
Report a serious adverse drug reaction (for hospitals) |
Section C.01.020.1 of the Food and Drug Regulations and section 62 of the Medical Devices Regulations, require hospitals to report to Health Canada all serious adverse drug reactions (ADRs) and medical device incidents (MDIs) within 30 days of being documented within the hospital. This regulatory requirement only applies to hospitals. |
For researchers
Resource | Description |
---|---|
Product Monograph |
The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use. The Product Monograph includes three sections:
|
Search Clinical Information | After Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes. |
All resources
Resource | Description |
---|---|
Product Monograph |
The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use. The Product Monograph includes three sections:
|
Regulatory Decision Summary for Clinimix / Clinimix E |
The Regulatory Decision Summary explains Health Canada’s decision for the product seeking market authorization. The Regulatory Decision Summary includes the purpose of the submission and the reason for the decision. |
Search Clinical Information | After Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes. |
Report a side effect |
Side effects are troublesome symptoms or feelings that you may not expect that show up when you are taking a medicine. All suspected side effects should be reported, especially those that are:
|
Report a serious adverse drug reaction (for hospitals) |
Section C.01.020.1 of the Food and Drug Regulations and section 62 of the Medical Devices Regulations, require hospitals to report to Health Canada all serious adverse drug reactions (ADRs) and medical device incidents (MDIs) within 30 days of being documented within the hospital. This regulatory requirement only applies to hospitals. |
Resource | Description |
---|---|
Product Monograph |
The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use. The Product Monograph includes three sections:
|
Regulatory Decision Summary for Clinimix / Clinimix E |
The Regulatory Decision Summary explains Health Canada’s decision for the product seeking market authorization. The Regulatory Decision Summary includes the purpose of the submission and the reason for the decision. |
Report a side effect |
Side effects are troublesome symptoms or feelings that you may not expect that show up when you are taking a medicine. All suspected side effects should be reported, especially those that are:
|